DUSP6 and acute lymphoblastic leukemia: Perhaps the most provocative series of experiments presented in this study involve the use of a pharmacological inhibitor of DUSP6/MKP-3 activity to validate the hypothesis that this phosphatase might be a therapeutic target in human ALL.